191 related articles for article (PubMed ID: 30870043)
1. Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.
Mochizuki K; Kawana S; Yamada S; Muramatsu M; Sano H; Kobayashi S; Ohara Y; Takahashi N; Hakozaki M; Yamada H; Hashimoto Y; Kikuta A
Pediatr Hematol Oncol; 2019 Feb; 36(1):17-27. PubMed ID: 30870043
[TBL] [Abstract][Full Text] [Related]
2. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract][Full Text] [Related]
3. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
5. Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: Implications for immunotherapy.
Zhu H; Gu S; Yin M; Shi M; Xin C; Zhu J; Wang J; Huang S; Xie C; Ma J; Pan C; Tang J; Xu M; Bai XF
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921877
[TBL] [Abstract][Full Text] [Related]
6. Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients.
Li X; Chen Y; Liu X; Zhang J; He X; Teng G; Yu D
Int Immunopharmacol; 2017 Mar; 44():153-159. PubMed ID: 28103502
[TBL] [Abstract][Full Text] [Related]
7. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
[TBL] [Abstract][Full Text] [Related]
8. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S; Adhikary P; Li G; Cheng K
Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
10. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
Xie L; Chen C; Liang X; Xu J; Sun X; Sun K; Yang R; Tang X; Guo W
Orthop Surg; 2023 Mar; 15(3):829-838. PubMed ID: 36519392
[TBL] [Abstract][Full Text] [Related]
11. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.
Haymaker CL; Wu RC; Ritthipichai K; Bernatchez C; Forget MA; Chen JQ; Liu H; Wang E; Marincola F; Hwu P; Radvanyi LG
Oncoimmunology; 2015 Aug; 4(8):e1014246. PubMed ID: 26405566
[TBL] [Abstract][Full Text] [Related]
12. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.
Koirala P; Roth ME; Gill J; Chinai JM; Ewart MR; Piperdi S; Geller DS; Hoang BH; Fatakhova YV; Ghorpade M; Zang X; Gorlick R
Sci Rep; 2016 Aug; 6():31154. PubMed ID: 27531281
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
14. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
Tanzarella S; Lionello I; Valentinis B; Russo V; Lollini PL; Traversari C
Cancer Immunol Immunother; 2004 Jun; 53(6):519-24. PubMed ID: 14727086
[TBL] [Abstract][Full Text] [Related]
16. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.
Aubert N; Brunel S; Olive D; Marodon G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208480
[TBL] [Abstract][Full Text] [Related]
17. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
19. [Lymphocyte subpopulations in malignant bone tumors and their relation to the immune response to the tumor].
Kosmiadi GA; Grigor'eva MP; Govallo VI
Vopr Onkol; 1981; 27(2):43-7. PubMed ID: 6971012
[TBL] [Abstract][Full Text] [Related]
20. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
